Compare PSQH & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSQH | IMMP |
|---|---|---|
| Founded | 2021 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 31.5M |
| IPO Year | 2021 | 2012 |
| Metric | PSQH | IMMP |
|---|---|---|
| Price | $3.39 | $3.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.6K | ★ 144.1K |
| Earning Date | 11-05-2026 | 09-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,685,987.00 | N/A |
| Revenue This Year | $81.45 | N/A |
| Revenue Next Year | $35.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1096.61 | N/A |
| 52 Week Low | $0.36 | $0.26 |
| 52 Week High | $6.94 | $5.36 |
| Indicator | PSQH | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 60.14 |
| Support Level | $0.51 | $2.65 |
| Resistance Level | $5.73 | $5.36 |
| Average True Range (ATR) | 0.35 | 0.23 |
| MACD | -0.12 | -0.15 |
| Stochastic Oscillator | 5.61 | 9.94 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.